Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11230713 Oligonucleotide compounds for targeting huntingtin mRNA

Patent 11230713 was granted and assigned to University of Massachusetts on January, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

University of Massachusetts

Current Assignee

University of Massachusetts

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

112307130

Patent Inventor Names

Julia Alterman0

Neil Aronin0

Anastasia Khvorova0

Date of Patent

January 25, 2022

Patent Application Number

168115800

Date Filed

March 6, 2020

Patent Citations Received

‌

US Patent 12077755 Bioactive conjugates for oligonucleotide delivery

‌

US Patent 11702659 Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders

‌

US Patent 11753638 Conjugated oligonucleotides

‌

US Patent 11767527 Modified oligonucleotides targeting SNPs

‌

US Patent 11993774 Huntingtin (HTT) iRNA agent compositions and methods of use thereof

‌

US Patent 12024706 Modified oligonucleotides targeting SNPs

Patent Primary Examiner

‌

Tracy Vivlemore

Patent abstract

This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11230713 Oligonucleotide compounds for targeting huntingtin mRNA

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API